TC Biopharm (Holdings) Plc (TCBP)
After hours:
| Previous close | 1.5500 |
| Open | 1.5400 |
| Bid | 1.6500 x 1400 |
| Ask | 1.6200 x 1200 |
| Day's range | 1.5400 - 1.6900 |
| 52-week range | 1.4600 - 88.0000 |
| Volume | |
| Avg. volume | 1,194,069 |
| Market cap | 3.741M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -16.2900 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 9.00 |
- PR Newswire
TC BioPharm Announces Closing of $5.5 Million Public Offering
TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced the closing of its previously announced public offering of 3,437,500 of its American Depositary Shares (the "ADSs") (or pre-funded warrants in lieu thereof), together with Series C warrants (the "Series C Warrants") to purchase up to 3,437,500 of its ADSs at a public offering price of $1.60 per AD
- PR Newswire
TC BioPharm Announces Pricing of $5.5 Million Public Offering
TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced the pricing of a public offering of 3,437,500 of its American Depositary Shares (the "ADSs") (or pre-funded warrants in lieu thereof), together with Series C warrants (the "Series C Warrants") to purchase up to 3,437,500 of its ADSs at a public offering price of $1.60 per ADS (or pre-funded warran
- PR Newswire
TC Biopharm Announces Corporate Restructuring, Reduction in Overhead
TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced a corporate restructuring plan to reduce costs and prioritize its pending lead US clinical programs.
